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Introduction: The most common adverse effects associated with bisphosphonates are renal toxicity, acute-phase
reactions, gastrointestinal toxicity, osteonecrosis of the jaw, transitory fever and uveitis. We report a unique adverse
case of vasculitis induced by clodronate.
Case presentation: A 61-year-old Caucasian woman developed bilateral renal ischemia after kyphoplasty and
clodronate treatment for lumbar vertebral fracture. Tests revealed a vasculitis due to clodronate treatment. The
antithrombotic and immunosuppressive drugs allowed us to reduce the extent of the renal ischemia. In the
following months the increased auto-antibodies returned to the healthy physiological range, but the chronic renal
failure persisted.
Conclusions: Drug-induced vasculitis is an inflammation of blood vessels caused by the use of various
pharmaceutical agents. The spectrum of drug-induced vasculitis can range from cutaneous rashes to fatal
multi-organ involvement. To the best of our knowledge this is the first documented case of drug-induced vasculitis
caused by clodronate in the literature. Previously, it was verified that clodronate injection could increase the
pro-apoptotic action on immune cells. Further studies are necessary to clarify the role of bisphosphonates on
drug-inducing vasculitis.
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Clodronic acid, a first-generation bisphosphonate, has
been successfully used in the treatment of high bone-
turnover states, Paget’s disease and osteolytic bone me-
tastases [1]. It is a synthetic analogue of pyrophosphate,
an endogenous regulator of bone mineralization, which
contains two phosphanate groups that allow recognition
by osteoclasts and macrophage membranes [2]. The
interaction between osteoclasts and clodronic acid is re-
sponsible for the inhibition of the ADP and/or ATP (ad-
enosine-diphosphate and/or adenosine-5′-triphosphate)
mitochondrial translocation activity, bone remodeling of
the matrix and may also induce apoptosis [3]. The* Correspondence: angelanotarnicola@yahoo.it
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distribution, and reproduction in any mediumclodronic acid is able to develop an anti-inflammatory ac-
tion through the inhibition of I-κB enzyme which is in the
macrophage cytoplasm and is responsible for the release
of interleukin-1 beta, interleukin-6 and tumor necrosis
factor-alpha, all of which play a central role in bone re-
modeling. Furthermore, clodronic acid induces an activa-
tion of an inflammatory cascade and attracts new
leukocytes to the inflammation [4,5]. The most common
adverse effects associated with bisphosphonates are renal
toxicity, acute-phase reactions, gastrointestinal toxicity
and osteonecrosis of the jaw. Less frequently there are
cases of transitory fever and uveitis [6-8].
Our case documents a developing progressive necrosis
of both kidneys after clodronic injection until now never
described in the literature. Our clinical research allowed
us to make a new pathogenetic hypothesis.
Case presentation
A 61 year-old Caucasian woman (height 150cm, weight
50Kg), in good general health, suffered a lumbar spinentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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X-ray and CT (computed tomography) scan showed a
fracture of the L2 vertebral body. We performed a kypho-
plasty with high density polymethylmethacrylate cement
(PMMA) (X-Pid, Medtronic Inc., Minneapolis, Minnesota,
USA). The dual-energy X-ray absorptiometry (DEXA)
exam confirmed the osteoporotic picture (T-score −4 DS).
At that point we started an osteoporosis treatment. Con-
sidering the DEXA results and clinical signs of the patient,
a bisphosphonate was administered [9]. To treat the post-
traumatic low back pain we started with clodronic acid
(200mg once every two weeks) through intramuscular in-
jection (Clasteon®, Abiogen Pharma S.p.A., Pisa, Italy) with
the intention of substituting the clodronic acid with one
of the other bisphosphonates (alendronic acid, risedronic
acid, ibandronic acid) by oral intake. In fact, clodronic acid
inhibits bone resorption and possesses good anti-
inflammatory and analgesic properties, useful in the acute
post-traumatic phase [10,11].
In the weeks following discharge, our patient began to
complain of fever, arthritis, low back pain and acute ab-
dominal pain and was hospitalized. A thorax-abdomen-
pelvic CT scan showed a left kidney ischemia (Figure 1A).
At first, we suspected that the renal artery might have
been closed by the PMMA cement used in her surgery
and that this may have been responsible for an artery
thrombosis. Contextually, we suspended the clodronate
treatment and we started anti-thrombotic therapy with
enoxaparin sodium (Clexane®, Sanofi-Aventis S.p.A.,
Milan, Italy) (4000IU once for two times a day for 30
days) and ticlopidine (Ticlid®, Sanofi-Aventis S.p.A,
Milan, Italy) (200mg tablets two times a day) after the
suspension of enoxaparin. We admitted the patient to
hospital to complete the diagnostic procedures (Tables 1
and 2). In the following days the blood tests showed
positivity for anti-neutrophil cytoplasmic antibody
(ANCA), anti-double-stranded deoxyribonucleic acid
(DNA) antibody (anti-ds DNA), anti-nuclear auto-
antibodies (ANA) and anti-myeloperoxidase antibodies
(MPO). At the same time, the CT scan showed anFigure 1 Computed tomography imaging. The first computed tomogra
tomography a few days later. An increasing of left renal ischemia tissue an
computed tomography after one year. A reduction of ischemic areas in boincrease in left renal ischemic tissue and a new ischemia
area in the right kidney (Figure 1B). An arteriography or
a kidney biopsy would have been useful to make a diag-
nosis. Considering kidney blood tests it was not possible
to carry out the arteriography due to the risk of inducing
a kidney failure [12]. The patient did not give the con-
sent to perform a kidney biopsy.
Although we suspected a link between the extension of
renal ischemia on the right kidney to the first thrombotic
event, the antibodies’ positivity supported a diagnosis of
immunological vasculitis, specifically systemic lupus ery-
thematosus (SLE). We, therefore, started an immunosup-
pression therapy with cyclophosphamide (Endoxan®,
Baxter S.p.A., Rome, Italy) (50mg, once a day, four days
a week). The follow-up blood test to check anti-
inflammatory and antibody parameters showed a progres-
sive return to normality, which was achieved by the six
month check-up.
However, the good clinical response to immunosup-
pressive therapy, the absence of clinical signs of SLE and
physiological range of antibodies allowed us to exclude
the previous immunological hypotheses. We suspected,
therefore, that the vasculitis may well have been caused
by the clodronate.
We suspended the immunosuppressive therapy and we
planned periodic check-ups. After one year the CT
showed a partial reduction of renal ischemia (Figure 1C),
even though the chronic renal failure persisted. We did
not detect any increase in auto-antibodies or any onset
of pathologic events.
Discussion
In this case, characterized by bilateral kidney necrosis,
we made a diagnosis of vasculitis caused by clodronate.
The primary diagnostic hypothesis was a renal throm-
bosis induced by cement embolism after kyphoplasty. In
the literature, similar cases following vertebroplasty are
reported as being due to cement overflow into paraver-
tebral vessels, eventually reaching the renal artery
[13,14]. In our case, this hypothesis was not supportedphy. An ischemic area in the left kidney (A). The computed
d a novel ischemia area in the right kidney (B). The follow-up
th kidneys (C).







Erythrocytes 3.41×106/ul 3.35×106/ul 3.75 to 4.54×106/ul
Leukocytes 7.03×103/uL 5.26×103/uL 4.0 to 9.32×103/uL
Platelets 336×103/uL 345×103/uL 150 to 500×103/uL
Creatinine 1.03mg/dL 1.00mg/dL 0.51 to 0.95mg/dL
GFR (glomerular filtration rate) 57mL/minute 61mL/minute >90mL/minute
Urea 34mg/dL 38mg/dL 15 to 38mg/dL
Total bilirubin 0.30mg/dL 0.30mg/dL 0.20 to 1.00mg/dL
S-Aspartate Aminotransferase (AST) 12U/L 17U/L 15 to 37U/L
S-Alanine Aminotransferase (ALT) 20U/L 22U/L 12 to 78U/L
S-Gamma Glutamine Transpepetidase (GGT) 25U/L 25U/L 5 to 55U/L
Albumin 3.4g/dL 3.3g/dL 3.4 to 5.0g/dL
Prothrombin time (PT) 1.07 ratio 1.04 ratio <1.20
Fibrinogen 365mg/dL 431mg/dL 200 to 400mg/dL
Activated partial thromboplastin time (aPTT) 1.21 ratio 1.17 ratio <1.20
Thrombin Time (TT) 1.12 ratio 1.07 ratio <1.20
D-dimers (DD) 0.7mg/dL 1.17mg/dL <0.5mg/dL
Lactate dehydrogenase (LDH) - 348U/L 84 to 246U/L
S-anti-dsDNA autoantibodies - 63.5U/mL <25U/mL (chemiluminescent assay)
S-anti-nuclear autoantibodies (ANA) - Positivity, pattern nuclear
speckled title 1/80
(immunofluorescent assay)
S-Autoantibodies anti-myeloperoxidase (MPO) - 58mm/h 1 to 20mm/h (immunoenzymatic assay)
Anti-neutrophil cytoplasmic antibodies (ANCA) - Positive Negative (immunofluorescent assay)
S-Autoantibodies to extractable nuclear antigens (ENA) - <0.5 Negative <1 (chemiluminescent assay)
S-Autoantibodies anti-smooth muscle (ASMA) - Negative Negative (immunofluorescent assay)
Urine exam
Hemoglobin (Hb) - >0.6mg/dl 0 to 0.02
Proteins - 0 0
Sediment - 5 to 10 red blood cells for field -
Table 2 Image techniques performed during the hospital stay
Instrumental exam Results
Thorax X-rays No pathological tissue signs and pleural effusion. Normal volume of heart.
echocardiography Left ventricle is normal (ejection fraction = 60%). It shows a low left atrial
dilatation with aortic and mitral insufficiency. There is no pericardial effusion.
Abdomen ultrasound The abdominal organs are normally. There is no artery disease; in fact, the
hepatic, kidney and spleen flow
and peripheral resistance are physiologic.
Thorax abdomen pelvic computed tomography (CT) scans The organs are normal.
Left kidney: reduction of the extension of previous necrosis area.
Right kidney: new ischemic area at the inferior tip.
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tests were normal. Moreover, unlike in vertebroplasty,
cement overflow is rare during kyphoplasty surgery. Fur-
thermore, the bilateral condition is further evidence
against the cement overflow hypothesis.
Further clinical exams showed the presence of anti-
bodies, such as anti-ANCA, anti-ds DNA, anti-ANA and
anti-MPO. Until this time, the patient had never under-
gone immunological tests. For this reason, we put for-
ward the hypothesis of immunologic vasculitis caused by
a silent form of systemic lupus erythematosus, activated
by clodronate. This hypothesis is supported by an ex-
perimental study that verified the pro-apoptotic effect of
clodronate, as well as its potential autoimmunity induc-
tion in SLE mononuclear circulating cells [15]. In ac-
cordance with the autoimmunity disease hypothesis, we
began immunosuppression therapy that stopped the pro-
gression of the disease. The kidney ischemia area and
auto-antibody levels decreased.
Further clinical research did not show other SLE clin-
ical signs. Given that drug-induced vasculitis (DIV)
could mimic the symptoms of SLE and the spectrum of
DIV can range from cutaneous rashes and petechiae or
single organ involvement to fatal multi-organ failure
with deaths commonly caused by massive pulmonary
hemorrhage, we excluded SLE [16]. At this point we hy-
pothesized vasculitis induced by clodronate.
Until now, no cases of DIV caused by clodronate have
ever been reported. The offending drug and its metabolites
may accumulate within neutrophils, bind to MPO and
modify the latter’s configuration which may spread
the autoimmune response to other autoantigens and
turn them into immunogenic neutrophil proteins (in-
cluding elastase, lactoferrin and nuclear antigens)
[17]. Some drugs could induce neutrophil apoptosis
[18]. Neutrophil apoptosis, moreover, in the absence
of priming, is associated with translocation of ANCA
antigens to the cell surface. This induces the produc-
tion of ANCAs, which in turn are able to bind to the
membrane-bound antigens, causing a self-perpetuating
constitutive activation by cross-linking PR3 or MPO
and Fcg receptors [19].
There is no standard approach to the treatment of DIV.
The first step is the discontinuation of the medication. For
patients with severe and active organ failure, intensive im-
munosuppressive therapy could improve organ function
and prevent progression to severe, irreversible disease.
In accordance with the literature, the diagnosis of DIV
for our case is defined by the following: (a) the signs and
symptoms of vasculitis were temporally related to using
the offending drug, and regressed with its discontinu-
ation; (b) blood levels of ANCA antibodies were positive;
and (c) medical conditions that mimic vasculitis were
excluded, especially malignancies [20].Conclusion
We report an adverse case of renal vasculitis induced by
clodronate. Considering the ample use on a global scale of
this drug for osteoporosis treatment, it is important to
highlight the possibility of this adverse effect. Our experi-
ence could help in making a quick diagnosis and the
timely start of the correct treatment in the future.
Consent
Written informed consent was obtained from our pa-
tient for publication of this case report and accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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